The Technical AnalystExchange: PNK Industry: Biotechnology
Inhibitor Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals
34.09% $0.118
America/New_York / 3 mai 2024 @ 15:18
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 20.30 mill |
| EPS: | -0.0200 |
| P/E: | -5.90 |
| Earnings Date: | May 10, 2024 |
| SharesOutstanding: | 172.02 mill |
| Avg Daily Volume: | 0.0095 mill |
| RATING 2024-05-03 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.90 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -5.90 | industry: PE -107.25 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.0514 (-56.43%) $-0.0666 |
| Date: 2024-05-04 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.107 - 0.129 ( +/- 9.32%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-08-11 | Osman Ronald E | Buy | 25 000 | Common Stock |
| 2023-05-05 | Ronald E Osman Irrevocable Trust Iii | Sell | 0 | Common Stock |
| 2023-05-05 | Tpb 2012 Llc | Buy | 0 | Common Stock |
| 2023-05-05 | Tpb 2012 Llc | Sell | 0 | Common Stock |
| 2023-05-05 | Mcnulty James A | Buy | 20 101 057 | Common Stock |
| INSIDER POWER |
|---|
| -57.75 |
| Last 91 transactions |
| Buy: 128 793 757 | Sell: 121 688 284 |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.118 (34.09% ) |
| Volume | 0.0002 mill |
| Avg. Vol. | 0.0095 mill |
| % of Avg. Vol | 2.11 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For INTI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
INTI
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.